🧪Trial version — For internal lab review only. Not for clinical or production use.
VaxIQ/RSV (Adults/Maternal)
← Back to VaxIQ

RSV (Adults/Maternal)

RSV Vaccine — Adults and Maternal (Abrysvo/mRESVIA)

Tier 2 · ExtendedVaccineCuration in progress

Platform: Prefusion F protein subunit / mRNA

Vaccine that protects older adults and newborns against respiratory syncytial virus (RSV), a leading cause of lower respiratory tract infections.

RSVprefusion FmaternalneonatalAbrysvo

Immunology Sections

Curated section analysis in progress

Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.

MechanismImmune ResponseMolecular & Immune SignaturesCorrelates of ProtectionOpen QuestionsImmunogenicitySafetyInfection Immunology

Wikipedia Overview

Full article ↗

A respiratory syncytial virus vaccine, or RSV vaccine, is an annual vaccine that protects against respiratory syncytial virus. RSV affects an estimated 64 million people and causes 160,000 deaths worldwide each year.

PubMed Literature

Search PubMed ↗

No PubMed results retrieved.

Semantic Scholar

Search S2 ↗

No Semantic Scholar results retrieved.